Teva Pharmaceuticals (Switzerland)

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Ralf Reilmann, Andrew McGarry, Igor D. Grachev et al. · The Lancet Neurology · 2018 · 104 citations

Neurodegenerative Diseases, Medicine, Psychotropic Medication +6

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

Frank Schneider, Margaret Bradbury, Thomas A. Baillie et al. · Clinical and Translational Science · 2020 · 44 citations · Full text

Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington disease

Shani Cohen, Zeev Waks, Jordan J. Elm et al. · BMC Medical Informatics and Decision Making · 2018 · 42 citations · Full text

Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices

Mark Forrest Gordon, Igor D. Grachev, Itzik Mazeh et al. · Digital Biomarkers · 2019 · 39 citations · Full text

Wearable System, Physical Activity, Accelerometer +20

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects

Frank Schneider, Lavi Erisson, Hooman Beygi et al. · British Journal of Clinical Pharmacology · 2018 · 39 citations · Full text